Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063211 | 0.92 | KMT2A (0.38) | ARKMT2AALOX12MAPTNPSR1 | |
| SCHEMBL3066117 | 0.87 | NPSR1 (0.41) | KMT2AMAPTNPSR1MEN1CYP1A2 | |
| SCHEMBL3063123 | 0.86 | TAAR1 (0.35) | KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL3053121 | 0.83 | CCR2 (0.38) | KMT2AMAPTMEN1HPGDALDH1A1 | |
| SCHEMBL3067257 | 0.80 | NPSR1 (0.41) | KMT2AMAPTKDRNPSR1MEN1 | |
| SCHEMBL3073957 | 0.79 | HPGD (0.34) | ARKMT2AKDRHPGDALDH1A1 | |
| SCHEMBL3068887 | 0.79 | SMN1; SMN2 (0.40) | KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3074091 | 0.79 | KMT2A (0.36) | ARKMT2AALOX12MAPTMEN1 | |
| SCHEMBL1873945 | 0.77 | KMT2A (0.34) | KMT2AMAPTKDRMEN1HPGD | |
| SCHEMBL3076554 | 0.77 | KMT2A (0.37) | KMT2AMAPTNPSR1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | claimed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | claimed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | claimed |
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | C3AR1, CBR3, C1S | AR 2545/4885KMT2A 3241/4885ALOX12 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.